Effect of rosiglitazone on osteoclastogenesis: an in vitro study
Fei XU,Yong-hui DONG,Feng-jin GUO,An-min CHEN,Shi-long HUANG
DOI: https://doi.org/10.3760/cma.j.issn.1674-5809.2012.09.010
2012-01-01
Abstract:Objective To investigate the effect of rosiglitazone on osteoclastogenesis.Methods Monocytes from bone marrow were isolated from the C57BL/6 mice and induced to differentiate into osteoclasts. Meanwhile,osteoclasts were incubated in the control group ( G1 ),0.5 μmol/L rosiglitazone (G2) and 2.0 μmol/L rosiglitazone (G3).Four days after cell culture,tartrate resistant acid phosphatase (TRAP) staining,osteoclast cell counting,real-time PCR analysis and quantitative measurement of TRAP activity were respectively done.Results For the number of osteoclastogenesis,the G2 and G3 group were significantly increased compared to the G1 group ( G1:32 ± 5,G2:54 ± 5,G3:72 ± 5,F =82.43,P <0.05 ) ; for TRAP activity assay,the G2 and G3 group were also increased compared to G1 group( G1:2.32 ±0.14,G2:2.83±0.08,G3:3.35±0.10,F=108.12,P<0.05).The gene expression in osteoclast,such as peroxisome proliferator activated receptor gamma,cathepsin k,c-fos and c-jun,were increased in rosiglitazone groups compared to the control group( F value was 33.50,37.46,53.73,39.77,respectively,all P < 0.05 ).Conclusion Rosiglitazone may increases osteoclastogenesis by cell proliferation.